Background: Both bevacizumab and erlotinib have clinical activity in non-small-cell lung cancer (NSCLC). Preclinical data suggest synergistic activity.
introduction
The prognosis for patients with advanced non-small-cell lung cancer (NSCLC) remains poor. Platinum-based combination chemotherapy has reached an efficacy plateau from which it will not ascend by its own [1] . For several reasons, the combination of bevacizumab and erlotinib is of interest in NSCLC. First, preclinical and clinical data indicate that antivascular endothelial growth factor (VEGF) and anti-epidermal growth factor receptor (EGFR) therapies have at least an additive antitumor effect [2, 3] . Secondly, the combination has proven to be well tolerated even when both are administered at their recommended phase II dose [4] . Finally, both erlotinib as single agent and bevacizumab in combination with cytotoxic chemotherapy are of proven benefit in the clinical management of advanced NSCLC [4] [5] [6] .
Objective response rates (ORRs), as determined by RECIST, obtained in phase II studies define whether a drug is moved toward phase III testing [7] . In contrast to traditional anticancer agents, the effects of these agents, especially bevacizumab, are cytostatic rather than cytotoxic [8] [9] [10] . Therefore, determining the activity of both agents by anatomical criteria alone probably underestimates their activity. The 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG-PET) studies may find evidence of anti-neoplastic activity within a week after initiation of treatment before changes in tumor volume can be detected [11] . Effects of drugs on tumor (micro)vasculature may be determined by dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) [12, 13] .
The aim of this study was to evaluate the efficacy of erlotinib and bevacizumab in first-line treatment of advanced NSCLC as determined by the non-progression rate (NPR) at 6 weeks. Secondary end points included ORR, safety, overall survival (OS) and progression-free survival (PFS) and the relation of molecular imaging-derived parameters with PFS and response.
patients and methods
patient eligibility
Key eligibility criteria were stage IIIB (pleural effusion) or IV nonsquamous NSCLC; no prior antitumor therapy; measurable disease (RECIST); Eastern Cooperative Oncology Group performance status (PS) of two or less and adequate hematologic, renal and hepatic function.
Key exclusion criteria were evidence of tumor invading major blood vessels; presence of a cavitating lesion; major surgical procedure, open biopsy, significant injury or radiotherapy within 28 days; serious nonhealing wound or ulcer; active peptic ulcer disease; evidence of bleeding diathesis, coagulopathy or history of ‡grade 2 hemoptysis; proteinuria ‡2+; brain metastasis or spinal cord compression unless previously treated with evidence of stable disease (SD) for >2 months; treatment with anticoagulants for therapeutic purposes; ongoing treatment with aspirin (>325 mg/day) or other medications known to predispose to gastrointestinal ulceration and any uneven systemic disease.
Written informed consent was obtained from all patients before inclusion.
study design and treatment
The study is a non-randomized phase II study, carried out at three university medical centers in The Netherlands. The study was approved by the institutional medical ethics review board of each participating center.
Patients were treated with bevacizumab 15 mg/kg as an i.v. infusion every 3 weeks and erlotinib 150 mg orally daily. No dose reductions of bevacizumab were allowed. Dose reductions of erlotinib were according to the label. Patients remained on treatment until disease progression, unacceptable toxicity and/or patient refusal. In case of documented tumor progression, patients received further treatment as per investigator's decision.
study assessments
Toxicity was scored every 3 weeks during treatment according to the common toxicity criteria adverse events version 3.0. Tumor response was measured with computed tomography (CT) (RECIST) every 6 weeks until disease progression. Objective responses were confirmed after at least 4 weeks.
exploratory end points
Imaging with CT, DCE-MRI and FDG-PET was carried out at baseline and after 3 weeks of treatment (just before bevacizumab infusion). Size was measured with CT and response defined by RECIST 1.0, tumor metabolism (SUV) with FDG-PET and a combined measure of perfusion and permeability (the endothelial transfer constant, K trans ) with DCE-MRI. Dynamic FDG-PET studies were carried out selectively at VU University Medical Center, whereas the other centers applied a static whole body FDG-PET protocol. (For imaging acquisition: see supplementary material available in Annals of Oncology online.)
tissue biomarkers
Mutation analysis of EGFR (exon [19] [20] [21] and KRAS (exon 1) was carried out on extracted tumor DNA. Formalin-fixed and paraffin-embedded tumor tissue sections were manually microdissected, and total genomic DNA was isolated using QIAamp DNA extraction kits (Qiagen, Venlo, The Netherlands). Nested polymerase chain reaction sequencing was carried out using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA), and the ABI PRISM 310 Genetic Analyzer (Applied Biosystems) [14] .
statistical considerations and analytical plan
The primary end point of the study was NPR (RECIST) at 6 weeks. This end point was used previously and it was shown that it is predictive for clinical benefit [15, 16] . To be able to discontinue the trial early if treatment showed insufficient activity, a two-stage design was implemented (Simon's optimal design; p0 = 40%, p1 = 60%, alpha = 0.05, beta = 0.20). A total of 46 patients would be entered and the treatment was declared to have sufficient activity to deserve further evaluation if at least 24 patients did not progress. A first analysis was made after 16 patients were included; if nine or more patients of them progressed within 6 weeks, the study would be stopped. Patients without post baseline tumor assessments were regarded as progressive. The analysis for the primary efficacy end points was based upon all registered subjects who received at least one dose of study treatment.
PFS was defined as the time from the start of the treatment to the date of the first documented progression in terms of RECIST or the date of death. OS was determined from the date of the start of the treatment to the date of death irrespective of the cause of death. Patients who had not progressed or died at the time of the analysis were censored at the date of last contact. The Kaplan-Meier method was used to plot PFS and OS. Predefined cut-off points were used and curves compared by log-rank testing.
Imaging results are presented as percentage change from the baseline value. Predefined cut points for imaging studies were based on reproducibility data. A 20% cut point was used for positron emission tomography (PET) (i.e. values outside 1.96 · standard deviation) [17] , while a 40% cut point was used for DCE-MRI-derived K trans [18, 19] .
Statistical analyses were carried out using SPSS (version 15.0; SPSS Inc., Chicago, IL). Results are presented with 95% confidence intervals (CIs) and P values. A P value of <0.05 was considered to be significant.
results

patient characteristics
From January 2006 till March 2007, 50 patients were registered; 47 patients received at least one dose of study treatment. Three patients were ineligible after inclusion but before start of treatment (one pulmonary embolism, one tumor involvement of large blood vessel, one trachea-esophageal fistula). Patient characteristics are provided in Table 1 .
As at the time of analysis, 11 patients were alive, 3 patients were on treatment; 35 patients stopped treatment due to progressive disease (PD), 5 due to toxicity, 2 because of surgical intervention and 2 patients died before progression was estimated. Patients received a median of four cycles of bevacizumab (range 1-21). Median follow-up for all patients was 15.2 months.
efficacy
Of the first 16 patients, 11 were non-progressive at 6 weeks. Therefore, the study continued for further accrual. For all patients at 6 weeks, 35 of 47 patients (75%) showed no progression. Twelve patients (25%) fulfilled the criteria of an original article Annals of Oncology objective response with one complete response (CR). Progression was more frequently observed in patients without rash (50% of patients without rash versus 15% with any grade of rash, Pearson v 2 6.78; P = 0.012); no correlation was found with gender, PS or smoking history.
At progression, 27 patients received further chemotherapeutic treatment with a platinum doublet. Twenty patients received palliative care only of which six at their own request (one patient underwent complementary treatment). The major clinical characteristic that determined whether or not patients received further chemotherapy was clinical deterioration due to the progression; nine patients died within 1 month after progression.
secondary end points
Median PFS was 3.8 (95% CI 2.3-5.4) months. No significant differences were observed between males and females or (former) smokers and never smokers. Neither rash nor development of hypertension was related to PFS, but patients that developed proteinuria had a significant longer PFS (5.7, 95% CI 1.3-10.2, months versus 2.3, 95% CI 0.4-4.2, months; P = 0.04). Median OS was 6.9 (95% CI 5.5-8.4) months, with 11 patients censored. No survival difference was observed between females and males, patients with versus without rash, ever smokers versus never smokers and between patients with PS 0-1 or 2. Median duration of tumor response was 10.9 (95% CI 5.0-16.8) months.
safety Toxicity was mainly as expected (Table 2 ). But two patients discontinued treatment because of toxicity that was not prespecified as per protocol. One patient developed sudden increase of liver enzymes, thrombocytopenic purpura and renal function disturbances, mimicking the renal thrombotic microangiopathy syndrome caused by bevacizumab [20] . Ultimately, the patient died at home at day 16. Autopsy was not carried out. One patient had a sigmoid perforation that was successfully treated by surgery. The resection specimen showed no tumor on microscopic examination. No severe bleeding episodes were observed. Three grade 3/4 thromboembolic events were encountered, one pulmonary embolism and one cerebrovascular accident. The latter patient was on study for 8 months and had as best response SD. The CT scan of the brain at the time of the cerebrovascular accident did not reveal brain metastasis.
exploratory end points imaging. Patients were included for imaging evaluation when at least CT and FDG-PET were available at baseline and after 3 weeks of treatment. Forty patients were found eligible ( Figure 1) . The baseline characteristics of the patients selected for imaging evaluation were comparable to the intention-totreat group as depicted in Table 1 . Figure 2 shows an example of response assessment by the three imaging modalities. Nine of the 40 patients had a CR or partial response (PR) as best response according to RECIST. After 3 weeks of treatment, five of these nine patients were classified as responder by CT scan Patients with a metabolic response (SUV decrease >20%) at week 3 had longer PFS (9.7, 95% CI 1.8-17.6, months) than those without (2.8, 95% CI 2.0-3.5, months; P = 0.01) ( Table 3 and Figure 3) . A response as assessed by DCE-MRI at week 3 (K trans decrease >40%) did not predict for longer PFS (26 patients; 4.3, 95% CI 3.5-5.1, months versus 2.7, 95% CI 0-9.1, months; P = 0.63). Although patients with a response on CT at week 3 had a longer PFS, this was not significant (4.6, 95% CI 1.3-7.9, months versus 2.9, 95% CI 1.3-4.5, months; P = 0.08) (Figure 3) . tissue biomarkers. Sufficient paraffin-embedded tumor material was available for EGFR (exons 19-21) (n = 24) and KRAS mutation (n = 27) analysis. Five EGFR mutations were detected: four in exon 20 and one in exon 21. None of these mutations were known to be predictive for response to erlotinib. In 10 of 27 patients, a KRAS mutation was detected. No differences in ORR, or PFS, were observed between wild-type patients and those with a mutation in either EGFR or KRAS (Table 4) . discussion This is the first study reporting on the activity of the combination of erlotinib and bevacizumab in chemonaive patients with advanced NSCLC. The rationale for the clinical evaluation of this combination in NSCLC is provided by the antitumor activity of dual blockade of the VEGF and EGFR pathway both in vitro and in vivo. The primary end point, an NPR of 75%, was met. At the time of design of this study, several considerations led to the choice of this primary end point. First, a study investigating the efficacy of single-agent erlotinib employed a similar primary end point and demonstrated the feasibility of our approach [16] . Instead of the NPR at 8 weeks, the NPR at 6 weeks was chosen for the present study because of the three-weekly administration of bevacizumab. Secondly, large cooperative phase III trials investigating different cytotoxic regimen all report a PD rate in the order of 20%, suggesting that an NPR of 75% is a reasonable primary end point for biological treatment [21] . In addition, as these agents are believed to be cytostatic rather than cytotoxic, ORR may be a less suitable end point for phase II studies with these agents [15] . Two studies evaluated erlotinib-bevacizumab in randomized phase II trials in the relapse setting of NSCLC and observed median times to progression of 4.4 and 3.4 months, respectively [22, 23] . These figures are not different from our results and from that obtained in the latest phase III studies in NSCLC in the firstline setting using cytotoxic chemotherapy alone [1, 5, 24] . But recent phase III trials in comparable patient groups as our study, i.e. untreated non-squamous NSCLC, showed increased PFS (5.3-6.7 months) and OS (11.9-13.6 months) when these patients were treated with bevacizumab-or pemetrexedcontaining chemotherapy [5, 6, 24] . Although the combination of bevacizumab with erlotinib did significantly improve PFS when compared with erlotinib and placebo in a phase III study in pretreated NSCLC patients, this was not translated in a survival benefit [23] . Recent data show that adding erlotinib to bevacizumab in the maintenance treatment of advanced NSCLC significantly prolongs PFS when compared with placebo [25] . The ORR of 24.5% was not different from that what can be obtained with classical chemotherapy. Disappointingly however, in the study reported here, median OS was 6.9 months only. This disturbing figure calls into question the so-called 'window of opportunity studies' of novel agents in untreated patients with advanced NSCLC. Noteworthy is the fact that only half of the patients received further platinum-based chemotherapy upon progression of disease. This was mainly due to deterioration of PS due to disease progression and patient refusal. Although disappointing, this is comparable to recent maintenance trials in which 50%-60% of patients receive second-line original article Annals of Oncology chemotherapy [26] [27] [28] . Careful selection of patients, possibly by biomarkers [29] and PS [16] , for entry into this type of study is mandatory as are early stopping criteria (e.g. molecular imaging).
None of the 27 patients where tissue was available had 'classical' EGFR mutations that would have predicted for response to erlotinib alone. The relatively high number of exon 20 mutations in this study is likely to be a chance phenomenon as the mutation frequency of >200 samples tested with the same, internationally accepted, method in our laboratory is in line with previous reported data (E. Thunnissen, D. Heideman, unpublished data). In the relapse setting, ORRs of 13%-17% are reported for this combination in unselected patients [22, 23] , higher than may be expected with single-agent erlotinib [4] . The Iressa Pan-Asia Study (IPASS) study reported a 1.1% ORR in chemonaive, EGFR mutation-negative, advanced NSCLC patients when treated with single-agent gefitinib [30] and showed that only patients with activating EGFR mutations benefit from first-line treatment with EGFR tyrosine-kinase inhibitor (TKI). All patients in the IPASS study were selected on clinical characteristics and it was clearly shown that when mutation status is not known or when EGFR is wild type, patients should be offered standard chemotherapy instead of first-line EGFR TKI as median PFS was only 2 months for EGFR wild-type patients treated with gefitinib. Therefore, one may assume that dual inhibition of the EGFR and VEGF pathway exerts an antitumor effect in EGFR mutation-negative patients and this strategy may be applicable to a broader population of patients compared with EGFR TKIs alone. Remarkably, one PR was obtained in a patient harboring a KRAS mutation. Objective responses in patients with KRASmutated tumors upon treatment with EGFR TKIs alone are rare [31] and this finding illustrates the complexity of the effect size of mutations in different pathways on tumor response. These data suggest that simultaneous inhibition of both the EGFR and the VEGF pathway might overcome primary resistance to EGFR inhibitors. A hypothesis that is supported by recent results obtained in an in vitro model [32] .
A phase I/II study of bevacizumab-erlotinib showed that these agents can each be administered at their phase III dose and schedule [33] . Toxicity in our study was mainly as expected, but some serious adverse events occurred. One patient developed a colon perforation during treatment and another developed a thrombotic microangiopathy syndrome. Ten patients experienced grades 3-4 thrombotic events, including three pulmonary embolisms and one cerebro vascular accident. Other than these, the rate of grades 3-4 toxicity was <5%. These results are comparable with other studies that evaluated the bevacizumab and erlotinib combination in NSCLC [22, 33] . Rash was the predominant form of toxicity and correlated with PFS and OS, although not significantly.
In this study, efforts were made to correlate molecular imaging with clinical outcome. In phase II studies using cytotoxic chemotherapy, response rate as determined by anatomical criteria, i.e. RECIST, is frequently used as the primary end point. Anatomical imaging has been subject to criticism among others by a recent review that showed that <50% of the difference in survival in 191 phase III studies conducted in NSCLC could be explained by variability in response rate [34] . We and others have shown that clinical outcome to chemotherapy can be predicted early [35] and more robust by using response monitoring consisting of serial FDG-PET scanning [36] . Indeed, in this study we were able to show that response to targeted treatment as assessed by serial FDG-PET scanning early during treatment was significantly associated with PFS, whereas tumor response as assessed by CT was not. In particular, the finding that response assessment by FDG-PET scanning at 3 weeks is predictive for PFS, even in patients with clinical good prognostic characteristics, is of importance as this opens the possibility to halt experimental treatment in the window of opportunity studies in chemonaive NSCLC patients early in order not to jeopardize survival by ineffective treatment. CT, in contrast, showed SD at week 3 for 45% of patients with PR/CR as their best CT response, reflecting the underestimation of treatment effects at early response assessments. Second, three patients with PR at FDG-PET and SD at CT had a median PFS of 9.7 months, suggesting that FDG-PET is more discriminative. Antiangiogenic agents such as bevacizumab are thought to exert their antitumor effects by normalization of tumor vasculature, inhibition of lymphangiogenesis and reduction of intratumoral interstitial pressure, thereby allowing for improved delivery of therapeutics [37] . Several of these consequences of antiangiogenic treatment may be monitored with currently available techniques such as DCE-MRI. This is the first report in lung cancer showing that most tumors have a decrease in K trans value after 3 weeks of treatment, indicating an effect on the tumor vasculature. A similar finding was reported by Willet et al. in a study in 12 patients with rectal carcinoma treated with bevacizumab preoperatively [9] . original article
Annals of Oncology
However, in our study a decrease in K trans was not predictive for prolonged PFS.
In conclusion, in this phase II study in chemonaive advanced NSCLC, we observed a 75% NPR at 6 weeks following treatment with a combination of bevacizumab and erlotinib. In contrast, OS was disappointing and some serious toxic effects occurred. Tumor effects with these biologicals are readily measurable with PET.
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